Neftaly: Developing Cost-Effectiveness Analyses for Biomarker Interventions
Biomarker interventions are transforming healthcare by enabling earlier diagnosis, personalized treatments, and improved disease monitoring. However, integrating these innovations into health systems—especially in resource-limited settings—requires careful evaluation of their economic value. Cost-effectiveness analyses (CEA) provide critical insights into the benefits, costs, and overall value of biomarker-based interventions, guiding decision-makers toward sustainable health investments.
At Neftaly, we specialize in developing rigorous, context-sensitive cost-effectiveness analyses that inform policy, optimize resource allocation, and promote equitable access to biomarker technologies.
Importance of Cost-Effectiveness Analyses in Biomarker Interventions
- Informs Decision-Making: Helps policymakers prioritize interventions with the highest health impact per dollar spent.
- Optimizes Resource Use: Ensures efficient allocation of limited healthcare budgets.
- Supports Funding and Scale-Up: Provides evidence to justify investments from governments, donors, and private sectors.
- Enhances Health Outcomes: Identifies interventions that deliver maximum benefits to patients and populations.
Neftaly’s Approach to Developing Cost-Effectiveness Analyses
1. Comprehensive Data Collection
- Gather data on biomarker test costs, including reagents, equipment, labor, and training.
- Analyze clinical outcomes, such as improved diagnosis accuracy, treatment success rates, and reduced complications.
- Include direct and indirect costs, such as patient travel and productivity losses, for holistic assessment.
2. Contextualizing Economic Models
- Customize models to reflect local epidemiology, healthcare infrastructure, and cost structures.
- Consider varying scenarios, including different population groups, settings, and intervention scales.
- Incorporate sensitivity analyses to account for uncertainty and variability in data.
3. Collaboration with Stakeholders
- Engage health economists, clinicians, program managers, and policymakers in model development.
- Validate assumptions and results through stakeholder workshops and expert consultations.
- Align analyses with national health priorities and strategic plans.
4. Clear Communication of Findings
- Present results in accessible formats such as policy briefs, dashboards, and infographics.
- Highlight key metrics like cost per quality-adjusted life year (QALY) gained or cost per case detected.
- Provide actionable recommendations tailored to decision-makers and funders.
5. Continuous Evaluation and Updating
- Monitor real-world implementation outcomes to refine models.
- Update analyses as new biomarker technologies emerge and costs evolve.
- Support ongoing capacity building for local analysts and institutions.
Example of Impact
In a Neftaly-supported evaluation of a biomarker test for tuberculosis diagnosis, the cost-effectiveness analysis revealed:
- Reduced time to diagnosis by 50%, leading to earlier treatment initiation
- Cost savings from fewer hospitalizations and transmission events
- Favorable cost per QALY compared to traditional diagnostic methods
This evidence facilitated national adoption and donor support for scale-up.
Conclusion
Cost-effectiveness analyses are indispensable tools for maximizing the health and economic benefits of biomarker interventions. Neftaly’s expertise ensures these analyses are scientifically robust, contextually relevant, and policy-oriented, empowering stakeholders to make informed, sustainable decisions that advance global health equity.